



FOR IMMEDIATE RELEASE

Completed The First Subject in Clinical Study for Continuous Glucose Monitoring System in Hong Kong

[7 September 2016, Hong Kong] Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950) an integrated research-driven and market-oriented pharmaceutical group in China is pleased to announce that Powder Pharmaceuticals, Incorporated ("PPI"), an associated company of the Group, has successfully enrolled the first subject of its Clinical Study for Continuous Blood Glucose Monitoring System (CGM) in Hong Kong.

The clinical study is collaboration between The Chinese University of Hong Kong, EyeSense, and PPI. The first subject study was completed on 31 August at Phase I Clinical Trial Centre of The Chinese University of Hong Kong. This clinical study will perform blood glucose clamp study with multiple CGM devices for 10 subjects. The study expects to be completed in about 3 months.

"This clinical study is a major milestone for the validation of the CGM device development program," said Dr. Benjamin Li, CEO for Lee's PHARM. "This CGM medical device incorporates a highly innovative concept with potential to provide significant health benefits to people with diabetes and eliminate the need for painful finger pricking multiple times a day. Our team has developed this concept into a workable prototype for clinical study in less than a year. This medical device adds a new and promising product to Lee's PHARM's Group portfolio."

About Continuous Blood Glucose Monitoring (CGM)

EyeSense's continuous blood glucose monitoring (CGM) approach sets an important milestone in the diabetes field. The Company's innovative and highly accurate device is based on a novel optical sensing technology and initial patient studies have yielded very promising data. Accuracy, reliability, and extended lifetime of the device will enable patients to significantly improve their disease management at reduced costs and high comfort. EyeSense's technology has the potential to grow the CGM market significantly and to allow CGM availability for a large portion of the diabetes population.

About Powder Pharmaceuticals, Incorporated ("Powder")

Powder is an associated company of Lee's Pharmaceutical Holdings Limited based in Hong Kong and is developing products that utilize a proprietary needleless, painless, powder delivery technology and other medical devices. Powder intends to supply Zingo® globally through international business partners. Powder has successfully obtained approval from U.S. FDA in July 2013 for the manufacturing facilities in Hong Kong to produce Zingo® and market the product to U.S.

About Lee's Pharmaceutical Holdings Limited ("Lee's Pharm")

Lee's Pharm is a research-based Hong Kong biopharmaceutical company listed in Hong Kong with over 20 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's Pharm development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharm is available at www.leespharm.com.

About EyeSense AG

EyeSense™ AG is a venture-backed diagnostic device company based in Basel, Switzerland, and with operations near Frankfurt am Main, Germany. EyeSense was founded in 2006 as a spinout from Ciba Vision AG (a Novartis company), and develops diagnostic systems focusing on glucose testing for diabetic patients. In addition to glucose, the testing platform being developed by EyeSense has the potential to measure a broad variety of medical-relevant analytes in patients. See www.eyesense.com for more details.

Safe Harbour Statement

The performance and the results of operation of Lee's Pharm during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's Pharm. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's Pharm nor the Directors, employees or agents of Lee's Pharm assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialize or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com